Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$68.61 USD

68.61
5,192,404

-0.39 (-0.57%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $68.51 -0.10 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Retain DexCom (DXCM) Stock For Now

by Zacks Equity Research

DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.

    Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for JKH

    DexCom (DXCM) Dips More Than Broader Markets: What You Should Know

    by Zacks Equity Research

    DexCom (DXCM) closed at $413.22 in the latest trading session, marking a -1.13% move from the prior day.

    DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know

    by Zacks Equity Research

    DexCom (DXCM) closed the most recent trading day at $439.64, moving -0.2% from the previous trading session.

    Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?

    by Zacks Equity Research

    DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know

    by Zacks Equity Research

    In the latest trading session, DexCom (DXCM) closed at $405.40, marking a +1.81% move from the previous day.

    Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for JKH

    The Zacks Analyst Blog Highlights: Tesla, Fortinet, West Pharmaceutical Services, DexCom and Tractor Supply

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Tesla, Fortinet, West Pharmaceutical Services, DexCom and Tractor Supply

    Here's Why You Should Retain Glaukos in Your Portfolio Now

    by Zacks Equity Research

    Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.

    Tirthankar Chakraborty headshot

    5 Best Stocks From 100 Days of Coronavirus

    by Tirthankar Chakraborty

    Here're five big stock winners from the first 100 days of the coronavirus pandemic that ravaged the global economy and shook the stock market.

    The Zacks Analyst Blog Highlights: Reckitt Benckiser, Henkel AG, DexCom, Tencent and Peloton Interactive

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Reckitt Benckiser, Henkel AG, DexCom, Tencent and Peloton Interactive

    Trina Mukherjee headshot

    3 MedTech Stocks to Watch Amid Coronavirus Catastrophe

    by Trina Mukherjee

    Let's keep a watch on three stocks that have displayed strong performance amid market turmoil led by the ongoing pandemic.

    DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know

    by Zacks Equity Research

    DexCom (DXCM) closed the most recent trading day at $393, moving -1.44% from the previous trading session.

    Urmimala Biswas headshot

    Economic Recovery Debate Heats Up: 4 Sectors Holding Ground

    by Urmimala Biswas

    Here we discuss four sectors for which COVID-19 has opened up enormous growth prospects.

    Sriparna Ghosal headshot

    3 Diabetes Management Stocks in the Spotlight Amid Coronavirus

    by Sriparna Ghosal

    Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments

    DexCom (DXCM) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    In the latest trading session, DexCom (DXCM) closed at $385.17, marking a +1.23% move from the previous day.

    DexCom's (DXCM) G6 CGM System Gets CE Marking in Europe

    by Zacks Equity Research

    DexCom (DXCM) announces the receipt of CE Marking across Europe for its G6 CGM System.

    ABIOMED Gets FDA Nod for First-in-Human Trial of Impella ECP

    by Zacks Equity Research

    This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product line.

    Here's Why You Should Retain AmerisourceBergen Stock Now

    by Zacks Equity Research

    Investor confidence is high on AmerisourceBergen (ABC) stock, thanks to solid prospects.

    Here's Why You Should Retain Ecolab in Your Portfolio Now

    by Zacks Equity Research

    Investor confidence is high on Ecolab (ECL) stock, thanks to solid prospects.

    Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for JKH

    ABIOMED's (ABMD) Impella RP Receives FDA's EUA Clearance

    by Zacks Equity Research

    This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product portfolio.

    Sanghamitra Saha headshot

    Do You Always Look for Earnings Beat? 5 Sectors to Play

    by Sanghamitra Saha

    These sectors came up with stellar earnings beat in the recent cycle. Investors can play the associated stocks that delivered an earnings surprise.

    Here's Why You Should Add Accuray to Your Portfolio Now

    by Zacks Equity Research

    Investor confidence is high on Accuray (ARAY) stock, thanks to solid prospects.

    Here's Why You Should Add DexCom (DXCM) to Your Portfolio

    by Zacks Equity Research

    DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.